Stratification of patients requiring immunosuppressive treatment according to the clinical and/or immunological severity of their disease has become a vital part of treatment decision making for patients with PLA2R1-associated membranous nephropathy. This evidence concerns the gene PLA2R1 and membranous glomerulonephritis.